MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

NCT00266344 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Insomnia

Interventions

DRUG: MK0928, gaboxadol / Duration of Treatment 3 Weeks
DRUG: Placebo / Duration of Treatment 3 Weeks

Sponsor

H. Lundbeck A/S